Chronic Inflammation Treatment Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-

https://shorturl.at/WPwmH

The Global Chronic Inflammation Treatment Market is expected to reach at a Significant CAGR during the forecast period 2024-2031.

List of the Key Players in the Chronic Inflammation Treatment Market:

Pfizer Inc., NodThera, Abcentra, Evommune, Inc., Sterna biologicals, Halia Therapeutics, Inc., Amgen Inc., AstraZeneca, Takeda Pharmaceutical Company Limited and Annexon, Inc

Industry Development:

On August 7, 2023, Halia Therapeutics announced the completion of participant enrollment for its Phase I study (NCT05447546) evaluating HT-6184, its lead candidate for chronic inflammation treatment. HT-6184 is designed to inhibit NLRP3 inflammasome activity by targeting the NEK7 protein through an allosteric mechanism, potentially addressing a wide range of inflammation-driven diseases.

On April 26, 2023, Evommune, Inc., a clinical-stage biotechnology company, secured $50 million in Series B funding to advance its research and development of novel therapies for inflammatory diseases. The round was co-led by new investor Arix Bioscience, alongside EQT Life Sciences, SymBiosis, and other existing investors. Additional participants included Amplitude Ventures, a new investor, as well as Series A investors Andera Partners and Pivotal bioVenture Partners.

On June 20, 2023, Takeda released full results from its pivotal Phase 3 ADVANCE-CIDP 1 clinical trial evaluating HYQVIA (Recombinant Human Hyaluronidase with Immune Globulin Infusion 10%) as a maintenance therapy for older adults with chronic inflammatory demyelinating polyneuropathy (CIDP). Compared to placebo, HYQVIA demonstrated a clinically significant reduction in relapse rates and an extended time to recurrence, reinforcing its potential as an effective long-term treatment option.

Growth Forecast Projected:

The Global Chronic Inflammation Treatment Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Segment Covered in the Chronic Inflammation Treatment Market:

By Type: Nonspecific Proliferative, Granulomatous Inflammation (Foreign Body Granuloma, Infectious Granuloma

By Medications: Metformin, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (Naproxen, Ibuprofen, Aspirin), Statins (Simvastatin, Rosuvastatin), Corticosteroids (Cortisone, Prednisone), Herbal Supplements

By Chronic Inflammation Disease Type: Diabetes, Cardiovascular Diseases, Arthritis and Joint Diseases, Chronic Obstructive Pulmonary Disease (COPD), Allergies, Others

By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com